India's Sharon Bio-Medicine was issued a warning letter from the U.S. FDA to either pay its generic drug user fees due since 2013 or be barred from shipping products to the U.S., Business Standard newspaper reported. The letter refers to fees due under the Generic Drug User Fee Amendments of 2012, Business Standard said, to offset costs related to generic drug filings and manufacturing facility inspections. The Sharon facility in Dehra Dun, India, reportedly did not pay fees in 2013, 2014 and 2015, the newspaper said. The company was not immediately available for comment. Report | More from FiercePharmaManufacturing